#biopharmaceuticals #Singapore #WuXi XDC #BPD Conference

Conclusion of the 2025 BPD Singapore Conference

The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, hosted by WuXi XDC, took place from September 24-26, 2025. This prominent event gathered leaders from biopharmaceutical companies and research institutions across Europe, North America, China, and the Asia-Pacific region. The conference's key objective was to enhance collaboration between Chinese biopharmaceutical enterprises and their global counterparts, focusing on the advancement of process technologies for innovative drug production.

Keynote Addresses

During the conference, Dr. Chris Chen, Chairman of WuXi XDC and CEO of WuXi Biologics, emphasized the transformative impact of technological advancements within the biopharmaceutical sector. In his keynote address, he articulated how innovations such as smart processes and the adoption of new materials can optimize costs and improve efficiency, thereby providing a strategic vision for the industry's future. WuXi Biologics has consistently prioritized research and development, continually fostering technological innovation to quicken the pace of biopharmaceutical breakthroughs.

Dr. Jimmy Li, CEO of WuXi XDC, delivered the opening speech, outlining the rapid growth of the biopharmaceutical industry, particularly the emergence of complex therapies, such as bioconjugates. He highlighted the critical need to accelerate the transition from drug development to market availability, aiming to connect cutting-edge research with improved patient outcomes. His insights underscored the conference's theme of cultivating communication and cooperation among global pharma entities, suppliers, and research institutions, all to better serve patients worldwide.

Innovation and Development Forum

An essential feature of the conference was the symposium titled "XDC Innovation and Development," which convened renowned entrepreneurs and experts to discuss pioneering research and industrial practice. Among the highlights was a panel discussion on the theme of "Innovation, collaboration, and inspiration in bioconjugates," moderated by Dr. Jimmy Li. This discussion engaged various industry leaders, including Carl Deutsch from NBE Therapeutics and Dawn Benson from CytomX Therapeutics, as they explored both technological advancements and the future prospects for antibody-drug conjugates (ADCs).

Insights into Bioconjugate Technologies

The participants were particularly focused on the evolving landscape of bioconjugate drugs. With the ongoing advancements in biopharmaceutical technologies, the discourse shifted toward the transition from conventional ADCs to the more expansive concepts of XDCs. These innovations present new opportunities in precision medicine, with payloads now extending beyond traditional toxins to encompass oligonucleotides and other novel compounds.

Dr. Yuhua Hu, leading the CMC (Chemistry, Manufacturing, and Control) efforts for WuXi XDC in the US and EU, expounded on the company's pivotal role in supporting the internationalization of Chinese innovative drugs. He detailed WuXi XDC's comprehensive technology platform, which provides end-to-end solutions from drug discovery through commercial manufacturing, alongside its robust intellectual property protections and exceptional quality management systems.

Dr. Stuart Wang, Executive Director at WuXi XDC, addressed the challenges and strategic pathways for the successful internationalization of China’s ADCs. He noted that China's role in the global ADC landscape is becoming increasingly significant, with robust safety, quality, and compliance measures being paramount for potential collaborations.

Supplementary Activities and Factory Visit

Complementing the conference discussions were thematic seminars and company technology showcases. WuXi XDC also organized an exclusive site visit to its Singapore facility, allowing attendees to observe its cutting-edge capabilities, quality controls, and global service strategies firsthand.

The facility features advanced modular designs and world-class production lines that align with the highest global standards, compliant with the FDA, EMA, and NMPA regulations, thus enabling comprehensive management of drug development and delivery processes.

Moving Forward

As the conference wraps up, there is a strong anticipation for the implementation of new technologies and products, heralding further expansion of biopharmaceuticals into global markets. Such advancements are geared toward enhancing healthcare delivery and improving outcomes for patients around the world.

About WuXi XDC

WuXi XDC Cayman Inc. (stock code 2268.HK) is a recognized leader in the contract research, development, and manufacturing sector specializing in bioconjugates. The organization provides a broad array of innovative technologies tailored for the development of next-generation antibody-drug conjugates. Committed to advancing the R&D of these groundbreaking therapies, WuXi XDC offers comprehensive services from preclinical stages to commercial manufacturing. For further information, visit www.wuxixdc.com.